2013-09-03 15:18:54 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to Sinclair IS Pharma PLC (SPH) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering Sinclair IS Pharma PLC (SPH). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential Sinclair IS Pharma PLC investor.
Report Summary: Sinclair IS Pharma PLC is an above average quality company with a positive outlook. Sinclair IS Pharma PLC has strong business growth and is run by mediocre management. The trend in Sinclair IS Pharma PLC fair value exchange rate against its closest rated-competitor, GlaxoSmithKline plc, has been appreciating over the past 2 weeks. When compared to its closest competitor, Sinclair IS Pharma PLC shows similar overvaluation and is equally likely to outperform the market.
The report breaks down
the Total StockMark into its three components - business, management and price, performing an in-depth analysis of Sinclair IS Pharma PLC for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.